

Datasheet: MCA6145

Description:	HUMAN ANTI C5 (ECULIZUMAB BIOSIMILAR)
Specificity:	C5
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	h5G1.1
Isotype:	IgG2/4
Quantity:	0.2 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species	Human
Product Form	Human IgG2/4 (kappa) antibody - liquid
Preparation	Purified recombinant IgG prepared by affinity chromatography on Protein A from a mammalian cell line
Source	HKB-11
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.09% Sodium Azide (NaN ₃)
Approx. Protein Concentrations	IgG concentration 1.0 mg/ml
Immunogen	Human C5

Specificity

Human Anti-C5 alpha antibody, clone h5G1.1, is a research grade biosimilar of the monoclonal antibody drug eculizumab. It is a recombinant human IgG2/4 kappa antibody with variable regions from the therapeutic eculizumab antibody clone h5G1.1. This product is supplied in a research grade format, i.e. in PBS buffer with preservative, it is not manufactured or formulated in the same way as the therapeutic reference product. A preservative free version is available [on request](#).

Human Anti-C5 Antibody is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-eculizumab antibodies for example HCA312 and HCA313.

Eculizumab (Soliris) is a humanized IgG2/4 kappa antibody. The heavy chains are comprised of human IgG2 sequences in CH1, the hinge and the adjacent portion CH2, and human IgG4 sequences in the remaining part of CH2 and CH3. The drug is used to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired life-threatening disease of the blood characterized by destruction of red blood cells by the complement system. It also has approval as an orphan drug for treatment of atypical hemolytic uremic syndrome (aHUS). Eculizumab specifically binds to the terminal complement component 5 (C5) and inhibits the cleavage of C5 to C5a and C5b by the C5 convertase, which prevents the generation of the terminal complement complex C5b-9. Both C5a and C5b-9 cause the terminal complement-mediated events that are characteristic of PNH and aHUS. A 1:1 molar ratio of eculizumab to C5 is sufficient for C5 inhibition.

This product is NOT FOR THERAPEUTIC USE.

[View a summary of supporting anti-eculizumab antibody products](#)

Purity	>98% by SDS PAGE
Storage	This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C. Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
Guarantee	12 months from date of despatch
Acknowledgements	This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.
Health And Safety Information	Material Safety Datasheet documentation #10040 available at: https://www.bio-rad-antibodies.com/SDS/MCA6145 10040
Licensed Use	For <i>in vitro</i> research purposes and for commercial applications for the provision of <i>in vitro</i> testing services to support preclinical and clinical drug development. Any re-sale in any

form or any other commercial application needs a written agreement with Bio-Rad.

Regulatory

For research purposes only

Related Products

Recommended Useful Reagents

[HUMAN ANTI ECULIZUMAB \(HCA312\)](#)

[HUMAN ANTI ECULIZUMAB \(HCA313\)](#)

[HUMAN ANTI ECULIZUMAB:HRP \(HCA313P\)](#)

[HUMAN ANTI ECULIZUMAB \(HCA314\)](#)

[HUMAN ANTI ECULIZUMAB \(HCA315\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK001P\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M430196:240503'

Printed on 03 May 2024

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)